ClinicalTrials.gg
CompletedNCT06703463Updated Nov 25, 2024

A Drug-Drug Interaction Study of Diltiazem and MK-1167 in Healthy Adult Participants (MK-1167-006)

A Phase 1 interventional study of MK-1167 and Diltiazem in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-25.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Feb 2024, 2 years 9 months ago, and no results have been posted to the registry.
  • Registered 1 year 1 month after the study started (first participant enrolled Oct 2023, registered Nov 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
19 Years to 50 Years
Sex
All
01

Study summary

The goal of this study this study is to learn about the safety of MK-1167 and if people tolerate it. Researchers will compare what happens to MK-1167 in the body when it is given with and without another medicine called diltiazem.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to the first dosing based on participant self-reporting
  • (BMI) ≥18.0 and ≤32.0 kg/m\^2
  • Able to swallow multiple capsules
  • In good health

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • History or presence of second- or third-degree atrioventricular heart block (except in participants with a functional artificial pacemaker)
  • History or presence of sick sinus syndrome
  • History of cancer () within the past 5 years
  • Unable to refrain from or anticipates the use of any drugs, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to the first dosing
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    MK-1167 Period 1

    On Day 1 a single dose of MK-1167 will be administered.

    Drug: MK-1167

  • Experimental
    MK-1167 Period 2

    There will be a washout of at least 35 days between MK-1167 dosing in Period 1 and the first diltiazem dose in Period 2. In Period 2, diltiazem will be administered once daily (QD) for 49 consecutive days with a single dose of MK-1167 coadministered on Day 3.

    Drug: MK-1167 · Drug: Diltiazem

Interventions

  • Administered via oral capsule per dosing regimen.

  • Diltiazem hydrochloride administered at a dose of 240 mg QD via oral capsules.

06

What researchers measure

Primary outcomes

  1. Number of participants who experience one or more adverse events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 99 days

  2. Number of participants who discontinue study intervention due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 85 days

  3. Area under the concentration versus time curve from 0 to infinity after single dosing (AUC0-inf) of MK-1167 in plasma

    AUC0-inf of MK-1167 in plasma will be determined.

    Time frame: Predose, and at designated timepoints up to 50 days post-dose

Secondary outcomes

  1. Area under the concentration versus time curve from 0 to last quantifiable sample (AUC0-last) of MK-1167 in plasma

    AUC0-last of MK-1167 in plasma will be determined.

    Time frame: Predose, and at designated timepoints up to 50 days post-dose

  2. Maximum concentration (Cmax) of MK-1167 in plasma

    Cmax of MK-1167 in plasma will be determined.

    Time frame: Predose, and at designated timepoints up to 50 days post-dose

  3. Concentration at hour 24 (C24) of MK-1167 in plasma

    C24 of MK-1167 in plasma will be determined.

    Time frame: Predose, and at designated timepoints up to 24 hours post-dose

  4. Time to maximum concentration (Tmax) of MK-1167 in plasma

    Tmax of MK-1167 in plasma will be determined.

    Time frame: Predose, and at designated timepoints up to 50 days post-dose

  5. Apparent terminal half-life (t1/2) of MK-1167 in plasma

    t1/2 of MK-1167 in plasma will be determined.

    Time frame: Predose, and at designated timepoints up to 50 days post-dose

  6. Apparent clearance (CL/F) of MK-1167 in plasma

    CL/F of MK-1167 in plasma will be determined.

    Time frame: Predose, and at designated timepoints up to 50 days post-dose

  7. Apparent volume of distribution during terminal phase (Vz/F) of MK-1167 in plasma

    Vz/F of MK-1167 in plasma will be determined.

    Time frame: Predose, and at designated timepoints up to 50 days post-dose

07

Study locations

1 site
  • Celerion (Site 0002)
    Lincoln, Nebraska 68502, United States
08

References and documents

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Feb 2024, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2024
First posted
Nov 25, 2024
StartActual
Oct 17, 2023
Primary completionActual
Feb 2, 2024
CompletionActual
Feb 2, 2024
Last update
Nov 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06703463
Responsible party
Sponsor
First posted
Nov 25, 2024
Start date
Oct 17, 2023
Primary completion
Feb 2, 2024
Completion
Feb 2, 2024
Last update
Nov 25, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-1167

Start the discussion